Clinical Trials
207 trialsNCT04980495 2026-05-27
ADAPT NXT
argenx
Phase 3 Completed
NCT06517758 2026-05-27
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
Novartis
Phase 3 Recruiting
NCT06744920 2026-05-27
RELIEVE
Novartis
Phase 3 Recruiting
NCT06958939 2026-05-27
The Safety and Efficacy of S103 in the Treatment of Refractory Generalized Myasthenia Gravis
Tang-Du Hospital
Phase 1 Active not recruiting
NCT06463587 2026-05-22
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 3 Recruiting
NCT07039916 2026-05-22
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Immunovant Sciences GmbH
Phase 3 Recruiting
NCT07246564 2026-05-22
Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis
UCB Pharma
Phase 4 Recruiting
NCT07596784 2026-05-19
Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)
Alexion Pharmaceuticals, Inc.
Phase 3 Not yet recruiting
NCT07596901 2026-05-19
Study of Aritinercept in Patients With Generalized Myasthenia Gravis
Aurinia Pharmaceuticals Inc.
Phase 1/2 Recruiting
NCT06359041 2026-05-18
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
Cabaletta Bio
Phase 1/2 Active not recruiting
NCT06680037 2026-05-18
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
TG Therapeutics, Inc.
Phase 1 Recruiting
NCT07501702 2026-05-18
ETNA
Vertex Pharmaceuticals Incorporated
Phase 2 Recruiting
NCT07593911 2026-05-18
ArchAid-002
Beijing GoBroad Hospital
Phase NA Not yet recruiting
NCT04524273 2026-05-15
MINT
Amgen
Phase 3 Active not recruiting
NCT06193889 2026-05-15
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Kyverna Therapeutics
Phase 2/3 Recruiting
NCT06987539 2026-05-14
THYME
Amgen
Phase 2 Recruiting
NCT07337785 2026-05-12
CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
Tongji Hospital
Phase EARLY_PHASE1 Recruiting
NCT07526493 2026-05-12
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Tongji Hospital
Phase 1 Recruiting
NCT06055959 2026-05-08
ziMyG
UCB Pharma
Phase 2/3 Recruiting
NCT06149559 2026-05-08
roMyG
UCB Pharma
Phase 2/3 Recruiting
NCT06435312 2026-05-08
ziMyG+
UCB Pharma
Phase 3 Enrolling by invitation
NCT06540144 2026-05-08
An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis
UCB Pharma
Phase 3 Enrolling by invitation
NCT07217587 2026-05-08
EPIC
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06456580 2026-05-07
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
Vor Biopharma
Phase 3 Recruiting
NCT07085676 2026-05-06
Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
Hadassah Medical Organization
Phase 1 Recruiting
NCT06447597 2026-04-30
A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3 Recruiting
NCT07556120 2026-04-29
Efficacy and Safety of HN2301 in Patients With Generalized Myasthenia Gravis (MG)
Shenzhen MagicRNA Biotechnology Co., Ltd
Phase 1 Not yet recruiting
NCT05332210 2026-04-28
Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis
Harbour BioMed (Guangzhou) Co. Ltd.
Phase 3 Completed
NCT06392386 2026-04-27
ADAPT Jr SC
argenx
Phase 2/3 Recruiting
NCT04225871 2026-04-24
RAISE-XT
UCB Pharma
Phase 3 Active not recruiting
NCT05374590 2026-04-23
ADAPT Jr +
argenx
Phase 2/3 Enrolling by invitation
NCT07284420 2026-04-23
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
argenx
Phase 2 Recruiting
NCT05556096 2026-04-21
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT07304154 2026-04-21
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
Gilead Sciences
Phase 1 Recruiting
NCT05644561 2026-04-17
Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT07532707 2026-04-16
Efficacy of IVIG Versus PLEX in Myasthenic Crisis in Syria.
Damascus University
Phase NA Completed
NCT06414954 2026-04-13
SYNAPSE-MG
NMD Pharma A/S
Phase 2 Recruiting
NCT06754020 2026-04-13
TCM Tongue Diagnosis and Syndrome Differentiation in Myasthenia Gravis Compared to Healthy Controls
National Taipei University of Nursing and Health Sciences
Phase NA Recruiting
NCT07221838 2026-04-09
OCTAGON
Alexion Pharmaceuticals, Inc.
Phase 4 Recruiting
NCT07249632 2026-04-09
A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)
RemeGen Co., Ltd.
Phase 3 Recruiting
NCT07499323 2026-04-08
Talquetamab in Patients With Refractory Generalized Myasthenia Gravis
First Affiliated Hospital of Chongqing Medical University
Phase NA Not yet recruiting
NCT06704269 2026-04-06
Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
Novartis
Phase 1/2 Recruiting
NCT06607627 2026-04-01
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT06471361 2026-03-27
A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis
UCB Pharma
Phase 3 Completed
NCT05403541 2026-03-25
Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis
Immunovant Sciences GmbH
Phase 3 Active not recruiting
NCT06799247 2026-03-24
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
Cartesian Therapeutics
Phase 3 Recruiting
NCT06491238 2026-03-23
MG-Ex
HealthPartners Institute
Phase NA Recruiting
NCT07413835 2026-03-18
Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)
The Affiliated Hospital of Xuzhou Medical University
Phase NA Recruiting
NCT07463521 2026-03-17
MyVision
UCB Pharma
Phase 3 Not yet recruiting
NCT07478172 2026-03-17
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
University of Missouri-Columbia
Phase NA Recruiting